Status:
WITHDRAWN
Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer
Lead Sponsor:
Ronald M. Benoit, MD
Conditions:
Prostate Cancer
Eligibility:
MALE
Phase:
NA
Brief Summary
The standard options for men with very low risk prostate cancer include active surveillance and the standard treatment options for low risk disease, i.e. radical prostatectomy, external beam radiother...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate
- Clinical stage T1c-T2aN0M0
- Gleason score \<= 3+3=6
- prostate specific antigen (PSA) \<10 ng/ml
- \<= 2 cores positive out of a minimum of 12 cores sampled
Exclusion
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02290366
Start Date
November 1 2014
End Date
July 31 2022
Last Update
August 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC Mercy
Pittsburgh, Pennsylvania, United States, 15219